Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-Effectiveness Analysis of Tumor Testing for BRCA Pathogenic Variants in Epithelial Ovarian Cancer.

American journal of clinical oncology - 1 Jul 2025

Taylor Sarah E, Mai Phuong L, Donovan Heidi, Bell Sarah G, Rush Shannon K, Edwards Robert P, Buckanovich Ronald J, Smith Kenneth J

Abstract excerpt

OBJECTIVES: Approximately 15% of women with epithelial ovarian cancer (EOC) have a germline BRCA1/2 pathogenic variant. Genetic testing for BRCA is recommended for all EOC patients, but not routinely performed. This study estimates the cost-effectiveness of BRCA screening with primary tumor testing versus routine germline testing. METHODS: The model used literature-based probability estimates and published cost...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Ovarian Epithelial

Share to Cost-Benefit Analysis

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to Germ-Line Mutation

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 40138181
DOI: 10.1097/COC.0000000000001187

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-Effectiveness Analysis of Tumor Testing for BRCA Pathogenic Variants in Epithelial Ovarian Cancer.PMID 40138181Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?Semantic proximity Read ↗

Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer.Semantic proximity Read ↗

A review of the cost-effectiveness of genetic testing for germline variants in familial cancerSemantic proximity Read ↗

Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian CancerSemantic proximity Read ↗

Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer PreventionSemantic proximity Read ↗

Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.Semantic proximity Read ↗

Cost-effectiveness of testing for breast cancer susceptibility genes.Semantic proximity Read ↗

A discrete event simulation to evaluate the cost effectiveness of germline <i>BRCA1</i> and <i>BRCA2</i> testing in UK women with ovarian cancerSemantic proximity Read ↗

BRCA Testing in Asian Patients with Ovarian Cancer: Standard Clinical Practice or Mutation Prediction Model?Semantic proximity Read ↗

Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making.Semantic proximity Read ↗

Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.